This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831458. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Notes for editors – not for publication
If you would like more information, please contact the spokesperson at the UMC Utrecht.
Joris Prinssen: +31 6 2571 0234 firstname.lastname@example.org